Connect Biopharma Holdings reported cash from operations of -$15.92M and free cash flow of -$15.92M for the quarter ended Jun 2026, down 26.5% year over year. This cash flow statement covers 10 quarters of results from Mar 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -8.69M | 14.85M | -12.88M | -8.91M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M |
| Share-based Compensation | 1.32M | 1.99M | 2.02M | 1.40M | 0.94M | 0.95M | 0.92M | 0.92M | 1.20M | 1.26M |
| Cash from Operations | -0.59M | -7.70M | -13.01M | -2.32M | -9.96M | -12.59M | -17.41M | -11.25M | -16.00M | -15.92M |
| Depreciation, Depletion & Amortization | ||||||||||
| Amortizatization of Intangibles | 0.09M | 0.01M | 0.02M | 0.25M | 0.29M | 0.17M | 0.07M | 0.01M | 0.00M | |
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.16M | 0.16M | 0.18M | 0.16M | 0.17M | 0.17M | 0.18M | 0.18M | 0.16M | 0.16M |
| Change in Working Capital | ||||||||||
| Change in Receivables | 5.02M | -4.23M | -0.78M | -0.01M | 0.02M | -0.00M | -0.01M | 2.94M | ||
| Change in Account Payables | -1.84M | 0.16M | -0.15M | -0.04M | 0.47M | 1.48M | -0.30M | -0.03M | 2.34M | -2.29M |
| Change in Accured Expenses | 0.72M | -1.30M | -0.08M | -1.02M | -0.56M | 0.69M | 1.00M | 2.23M | -0.40M | 3.06M |
| Other Working Capital Changes | -1.21M | -0.04M | 1.49M | -2.02M | 1.29M | 2.24M | 1.81M | -1.23M | -0.26M | -2.12M |
| Investing Activities | ||||||||||
| Capital Expenditures | 0.00M | 0.29M | 0.15M | 0.31M | 0.08M | 0.30M | 0.03M | 0.19M | -0.00M | -0.00M |
| Sales of Property, Plant and Equipment | 0.00M | |||||||||
| Change in Acquisitions & Divestments | 9.25M | 3.50M | 2.00M | 13.34M | 14.38M | 11.00M | 6.00M | |||
| Cash from Investing Activities | 9.25M | 3.21M | -0.15M | -15.76M | -20.64M | 5.13M | 14.35M | 10.98M | 6.00M | -4.47M |
| Financing Activities | ||||||||||
| Other financing activities | 0.10M | 0.09M | 0.14M | 0.09M | 0.64M | 18.60M | 1.55M | |||
| Change in Capital Stock | ||||||||||
| Net Equity Issued and Repurchased | 0.00M | 0.02M | 0.14M | |||||||
| Misc. | ||||||||||
| Cash from Financing Activities | 0.12M | 0.11M | 0.00M | 0.16M | 0.21M | 0.71M | 17.62M | 1.33M | ||
| Exchange Rate Effect | -0.22M | 0.10M | 0.51M | -0.98M | 0.07M | 0.22M | 0.06M | 0.05M | 0.07M | 0.04M |
| Change in Cash | 8.44M | -4.26M | -12.65M | -18.96M | -30.52M | -7.08M | -2.79M | 0.50M | 7.69M | -19.02M |
| Free Cash Flow | -0.59M | -7.98M | -13.15M | -2.63M | -10.04M | -12.89M | -17.44M | -11.44M | -16.00M | -15.92M |
| Net Cash Flow | 8.66M | -4.36M | -13.15M | -17.98M | -30.60M | -7.30M | -2.85M | 0.45M | 7.62M | -19.06M |